Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

What happened: Vor Bio reported final two-year results from the Phase 3 TELIGAN trial of telitacicept in adults with IgA nephropathy, conducted in China by collaborator RemeGen. Why it matters: Vor Bio said the data reinforce the clinical potential of dual BAFF/APRIL inhibition as it advances global Phase 3 programs in myasthenia gravis and Sjögren's disease. Telitacicept received conditional approval in China in June 2026 for proteinuria reduction in primary IgAN. Market: -6.3% today ($62.65), -14.9% YTD, 0.7x vol — as of 07:45 UTC

Vor Bio reported final two-year results from the Phase 3 TELIGAN trial of telitacicept in adults with IgA nephropathy, conducted in China by collaborator RemeGen.

Vor Bio said the data reinforce the clinical potential of dual BAFF/APRIL inhibition as it advances global Phase 3 programs in myasthenia gravis and Sjögren's disease. Telitacicept received conditional approval in China in June 2026 for proteinuria reduction in primary IgAN. Market: -6.3% today ($62.65), -14.9% YTD, 0.7x vol — as of 07:45 UTC